PMID- 30366077
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 127
DP  - 2019 Jan 15
TI  - PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity 
      Cycle for melanoma treatment.
PG  - 161-174
LID - S0928-0987(18)30468-8 [pii]
LID - 10.1016/j.ejps.2018.10.021 [doi]
AB  - The Cancer-Immunity Cycle is a series of anticancer immune responses initiated 
      and allowed to proceed and expand iteratively. Paclitaxel (PTX) is a classic 
      chemotherapeutic agent, which could induce immunogenic cell death (ICD) to 
      trigger the Cancer-Immunity Cycle. However, the Cycle is severely impaired by 
      tumor cell immunosuppression of host T cell antitumor activity through the 
      programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 
      (PD-L1) (PD-1/PD-L1) immune checkpoint pathway. Here, we demonstrated that PTX 
      mediated the Cancer-Immunity Cycle could be enhanced by PD-L1 knockdown (KD) and 
      followed mTOR pathway inhibition in tumor cells. PD-L1 siRNA (siP) and the 
      hydrophobic chemotherapy drug PTX were co-delivered with a rationally designed 
      hybrid micelle (HM). We showed clear evidence that the HM-siP/PTX is capable of 
      delivering siP and PTX simultaneously to the B16F10 cells both in vitro and in 
      vivo. We demonstrated that HM-PTX/siP reduced the expression of PD-L1 and p-S6K 
      (a marker of mTOR pathway activation) both in vitro and in melanoma-bearing mice 
      and attenuated synergistically tumor growth by chemical toxicity, promoting 
      cytotoxic T-cell immunity and suppressing the mTOR pathway.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Tang, Xian
AU  - Tang X
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China.
FAU - Rao, Jingdong
AU  - Rao J
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China.
FAU - Yin, Sheng
AU  - Yin S
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China.
FAU - Wei, Jiaojie
AU  - Wei J
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China.
FAU - Xia, Chunyu
AU  - Xia C
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China.
FAU - Li, Man
AU  - Li M
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China.
FAU - Mei, Ling
AU  - Mei L
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China.
FAU - Zhang, Zhirong
AU  - Zhang Z
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China.
FAU - He, Qin
AU  - He Q
AD  - Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of 
      Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 
      610041, China. Electronic address: qinhe@scu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20181023
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Calreticulin)
RN  - 0 (Micelles)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptor, IGF Type 2)
RN  - 0 (cation-dependent mannose-6-phosphate receptor)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage/pharmacokinetics
MH  - B7-H1 Antigen/*genetics/metabolism
MH  - Calreticulin/metabolism
MH  - Cell Line, Tumor
MH  - Melanoma, Experimental/immunology/metabolism/*therapy
MH  - Mice, Inbred C57BL
MH  - *Micelles
MH  - Paclitaxel/*administration & dosage/pharmacokinetics
MH  - RNA, Small Interfering/*administration & dosage/pharmacokinetics
MH  - Receptor, IGF Type 2/metabolism
MH  - Ribosomal Protein S6 Kinases/metabolism
MH  - T-Lymphocytes/drug effects/immunology
OTO - NOTNLM
OT  - Cancer-Immunity Cycle
OT  - Immunogenic cell death (ICD)
OT  - PD-L1 knockdown
OT  - mTOR pathway
OT  - siRNA delivery
EDAT- 2018/10/27 06:00
MHDA- 2019/04/16 06:00
CRDT- 2018/10/27 06:00
PHST- 2018/08/15 00:00 [received]
PHST- 2018/10/18 00:00 [revised]
PHST- 2018/10/21 00:00 [accepted]
PHST- 2018/10/27 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
PHST- 2018/10/27 06:00 [entrez]
AID - S0928-0987(18)30468-8 [pii]
AID - 10.1016/j.ejps.2018.10.021 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2019 Jan 15;127:161-174. doi: 10.1016/j.ejps.2018.10.021. Epub 
      2018 Oct 23.